Cognitive Testing in Clinical Drug Trials: Successful Test Selection and Integration
Cognitive assessment has long been a key efficacy measure in clinical trials of indications such as Alzheimer’s disease. In the past few years, the use of cognitive efficacy measures has been extended to indications including Schizophrenia, Depression and Lewy body Dementias. The use of cognitive assessment has also been extended to the assessment of safety, especially in cardiology.
Cognitive assessment has been employed with variable success and a hallmark of failed examples has been the use of tests with poor reliability, validity and sensitivity. In this webinar we will review examples of both successful and failed case studies. We will conclude with recommendations for cognitive test selection and its successful integration into clinical drug trials.
This is an excellent opportunity to hear from a renowned cognition expert and gain a better understanding on the selection and successful integration of cognitive testing into therapeutic development programmes.
Upcoming start dates
Suitability - Who should attend?
Benefits of Attending
- Understand the increasing importance of cognitive testing in clinical drug trials
- Learn more about cognitive test selection and how to successfully integrate cognitive assessment in therapeutic development programmes
- Gain an opportunity to discuss the complexities of cognitive assessment with an expert in this field
Request information - obligation free
Customer Outreach Award
We believe that it should be easy for you to find and compare training courses.
Our Customer Outreach Award is presented to trusted providers who are excellent at responding to enquiries, making your search quicker, more efficient and easier, too.